KIR3DL1-HLA class I interactions influence immune responses in a range of settings, including hematopoietic cell transplantation (25, 26, 45, 46), viral infection (3, 29, 47, 48), cancer immunotherapy (49), and even neurological disease (50, 51). This evidence concerns the gene KIR3DL1 and cancer.